Stocks · News reference
NeOnc Technologies to be Featured on 'Health Uncensored with Dr. Drew'
NeOnc Technologies Holdings, Inc. announced it will be featured on the national television series 'Health Uncensored with Dr. Drew' to discuss its non-invasive drug delivery approaches for brain tumors.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NeOnc Technologies Holdings, Inc. Files Form 10-Q for Period Ending September 30, 2026
NeOnc Technologies Holdings, Inc. submitted its quarterly financial report (Form 10-Q) to the SEC for the period ending September 30, 2026.
8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filed: 2026-11-03 AccNo: 0001829126-26-011937 Size: 211 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company, will present data from two investigational brain cancer programs—intranasal NEO100 and oral NEO212—at the Society for Neuro-Oncology annual meeting on November 13, 2026. The company is advancing ambitious plans for a 500-patient international clinical trial across 30 hospitals in three countries, leveraging innovative drug delivery approaches and AI-assisted tumor modeling technology.
NeOnc Technologies to Present Clinical Data at Society for Neuro-Oncology Annual Meeting
NeOnc Technologies Holdings, Inc. announced it will present updated clinical data for its intranasal NEO100 and oral NEO212 programs at the 31st Annual Meeting of the Society for Neuro-Oncology.
NeOnc Technologies Outlines Plans for International Brain Cancer Clinical Trial
NeOnc Technologies Holdings is planning a significant expansion of its clinical research with a proposed trial targeting approximately 500 patients across 30 hospitals in three countries.